Sepsis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2017


Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. It is one of the leading causes of death among developed countries, with over 10% mortality rates in sepsis patients and over 40% in patients who develop septic shock. To manage sepsis, immediate interventions are required, which include infection control, hemodynamic restoration with fluid resuscitation and vasopressors, and other supportive care approaches. With the last FDA-approved drug for severe sepsis (Eli Lilly’s Xigris) withdrawn in 2011 due to its failure to show survival benefits, all current therapies for sepsis are either used off-label and/or are generically available. Therefore, opportunity exists for drug developers who can address key areas of unmet need. However, given the field’s limited understanding of sepsis pathophysiology, developers will likely face challenges during clinical development of their novel agents.


  • How large are the U.S. and EU5 sepsis patient populations, and how will their size change through 2026? What percentage of these patients progress to septic shock?
  • How are sepsis patients diagnosed and managed? What are the key current therapies prescribed for the treatment of sepsis and what drives their use?
  • How have the updated definitions for sepsis impacted diagnosis and treatment of sepsis and septic shock?
  • What are the key areas of unmet need and to what extent will they be fulfilled by the therapies currently in the pipeline?
  • What challenges will developers encounter when conducting clinical trials for drugs to treat sepsis? What clinical and commercial impact will emerging drugs have on the sepsis market through 2026?​​​​​​


Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Login to access report